Home/Filings/4/0001415889-18-000064
4//SEC Filing

HANSON GREGORY P 4

Accession 0001415889-18-000064

CIK 0001109196other

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 6:00 AM ET

Size

14.0 KB

Accession

0001415889-18-000064

Insider Transaction Report

Form 4
Period: 2018-01-08
HANSON GREGORY P
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2018-01-10$0.96/sh66,550$63,888411,815 total
  • Sale

    Common Stock

    2018-01-11$0.98/sh38,697$37,923373,118 total
  • Exercise/Conversion

    Restricted Stock Unit

    2018-01-08449,1590 total
    Common Stock (449,159 underlying)
  • Sale

    Common Stock

    2018-01-12$0.96/sh11,232$10,783361,886 total
  • Exercise/Conversion

    Common Stock

    2018-01-08+449,159478,365 total
Footnotes (7)
  • [F1]Represents conversion of restricted stock units into common stock upon vesting of such units granted on September 15, 2017 and October 2, 2017.
  • [F2]Represents a portion of the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II of the reporting person. This sale is mandated by the Issuer's election under the equity incentive plan to require satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.87 to $1.02 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.95 to $1.02 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.95 to $1.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer.
  • [F7]Restricted Stock Units vested on January 8, 2018, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date.

Issuer

MABVAX THERAPEUTICS HOLDINGS, INC.

CIK 0001109196

Entity typeother

Related Parties

1
  • filerCIK 0001186120

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 6:00 AM ET
Size
14.0 KB